Immatics N.V.

NASDAQ:IMTX

Biotechnology

Healthcare
$6.10 +1.58%

+$0.15 today

Market cap
$912.78M
Beta
1.30
P/E (TTM)
-5.3
EPS (TTM)
-$1.59
52W Low $5.05High $12.41

Volume 1.57M

Average 0.46M

IMTX Other Working Capital

Cash effect of changes in other operating assets and liabilities.

Immatics N.V.NASDAQ: IMTX

Other Working Capital · Q1 FY2026 · quarter ended Mar 2026

Other working capital turns positive

Q1 FY2026 other working capital was €1.18M, compared with -€16.11M a year earlier. Trailing-twelve-month other working capital was -€3.8M. Over 3 fiscal years it compounded at -9.3% a year.

Context

  • Other working capital amounted to 12.2% of revenue in FY2025, down 91.9 pp from a year earlier.
  • Other working capital increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly other working capital holds near €1.18M or moves back toward the trailing-twelve-month quarterly average of -€950.02K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
€1.18M+126.1% QoQ
Last fiscal yearDec 2025
-€5.87M-96.4% YoY
LTMMar 2026
-€3.8M-97.1% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+107.3%——
1 year-96.4%——
3-year CAGR-9.3%——
5-year CAGR——
10-year CAGR——

Other Working Capital history

EUR · from the cash flow

Latest · FY2025
(5.87M) EUR
Year-over-year change
+96.4%

Other Working Capital vs competitors

How IMTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -97.1% is the lowest of 10, against a peer median of -18.5%.
  • Other working capital amounts to 10.2% of revenue for IMTX, versus a peer median of 51.8%.
IMTX Competitors
Other Working Capital for IMTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$141.78M USD-18.5%—10.4%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$111.45M USD-20.1%+113.6%481.7%
JANXJanux Therapeutics, Inc.LTM Mar 2026$46.14M USD+312.2%+7.9%213.5%
DTILPrecision BioSciences, Inc.LTM Mar 2026$23.36M USD-49.6%—51.8%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$16.02M USD+649.3%+102.5%—
CLLSCellectis S.A.LTM Mar 2026$12.21M USD+0.4%—17.9%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$8.16M USD+273.8%+12.1%89.3%
IMCRImmunocore Holdings plcLTM Mar 2026$7.82M USD-75.2%—2.0%
IMTXImmatics N.V.LTM Mar 2026€3.8M EUR-97.1%-9.3%10.2%
LYELLyell Immunopharma, Inc.LTM Mar 2026$3.12M USD-33.0%-55.0%10071.0%
BNTXBioNTech SELTM Jun 2026€0 EUR——0.0%
Peer median (excluding IMTX) —-18.5%+12.1%51.8%

Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(93.34M)37.51M(94.65M)15.22M(188.69M)
Depreciation & Amortization5.26M6.97M7.23M12.23M11.91M
Deferred Income Tax11.15M4.52M06.13M0
Stock-Based Compensation26.4M22.57M20.71M17.64M0
Change in Working Capital(31.7M)37.26M81.63M(163.88M)(42.23M)
Accounts Receivables569K(429K)(2.98M)(1.76M)(232.45K)
Inventory00(84.24M)00
Accounts Payables(31.78M)45.56M84.24M0(36.13M)
Other Working Capital(483K)(7.87M)84.61M(162.11M)(5.87M)
Other Non-Cash Items433K(8.7M)3.31M(45.37M)49.36M
Operating Cash Flow(81.78M)100.13M18.23M(158.03M)(169.66M)
Capital Expenditures(5.66M)(6.22M)(30.96M)(16.48M)(6.3M)
Acquisitions (Net)551K(199.91M)000
Purchases of Investments(11.3M)(216.32M)(415.33M)(450.35M)(324.92M)
Sales of Investments24.45M12.7M414.74M314.44M528.16M
Other Investing Activities(551K)199.96M(8K)(206K)0
Investing Cash Flow7.49M(209.79M)(31.39M)(152.39M)196.7M
Debt Repayment(2.71M)(2.84M)(3.85M)(2.01M)0
Common Stock Issued94K134.48M90.4M343.01M96.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(7.93M)(2.04M)(21.31M)(2.84M)
Financing Cash Flow(2.61M)123.71M84.52M319.68M93.51M
Effect of Forex Changes2.37M1.48M(1.4M)9.01M16.56M
Net Change in Cash(74.54M)15.53M69.95M18.28M137.12M
Free Cash Flow(87.44M)93.92M(12.73M)(174.51M)(175.95M)

Immatics N.V.

NASDAQ:IMTX

Intrinsic Alpha fair value

Locked

Current Price

$6.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.